Michael Khan
Chief Executive Officer at Argonaute RNA Ltd.
Profile
Michael Khan is currently the Chief Executive Officer at Argonaute RNA Ltd.
He is also a member of Diabetes UK and HEART UK.
Previously, he was the Executive Director & Chief Medical Officer at Silence Therapeutics Plc from 2013 to 2016.
He also worked as the Head-Molecular Medicine & Associate Professor at the University of Warwick.
Dr. Khan holds a doctorate degree from University College London.
Michael Khan active positions
| Companies | Position | Start |
|---|---|---|
| HEART UK | Corporate Officer/Principal | - |
| Diabetes UK | Corporate Officer/Principal | - |
Argonaute RNA Ltd.
 Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Argonaute RNA Ltd. develops safe and reliable methods of temporarily silencing target genes in different tissue cells. The company is based in Bristol, UK. Michael Khan has been the CEO of the British company since 2021. | Chief Executive Officer | 2020-12-31 |
Former positions of Michael Khan
| Companies | Position | End |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 2016-06-16 |
| University of Warwick | Corporate Officer/Principal | - |
Training of Michael Khan
| University College London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Private companies | 3 |
|---|---|
| HEART UK | |
| Diabetes UK | |
Argonaute RNA Ltd.
Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Argonaute RNA Ltd. develops safe and reliable methods of temporarily silencing target genes in different tissue cells. The company is based in Bristol, UK. Michael Khan has been the CEO of the British company since 2021. | Commercial Services |
- Stock Market
- Insiders
- Michael Khan
